Sort by

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 23


Multiple testing. Part I. Single-step procedures for control of general type I error rates.

Dudoit S, van der Laan MJ, Pollard KS.

Stat Appl Genet Mol Biol. 2004;3:Article13. Epub 2004 Jun 9.


Why most published research findings are false.

Ioannidis JP.

PLoS Med. 2005 Aug;2(8):e124. Epub 2005 Aug 30.


Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients.

Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, Gori C, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of HIV Genotype Resistance Test (GRT) at National Institute for Infectious Diseases Lazzaro Spallanzani.

AIDS. 2005 Jul 1;19(10):1081-9.


Update of the Drug Resistance Mutations in HIV-1: 2005.

Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro J, Telenti A, Richman D.

Top HIV Med. 2005 Mar-Apr;13(1):51-7. Review.


No inherent association between minor mutations in HIV protease at baseline and selection of the L90M mutation at the time of the first virological failure.

Brumme CJ, Harrigan PR.

J Infect Dis. 2005 May 15;191(10):1778-9; author reply 1779-80. No abstract available.


HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach.

Harrigan PR, Wynhoven B, Brumme ZL, Brumme CJ, Sattha B, Major JC, de la Rosa R, Montaner JS.

J Infect Dis. 2005 Apr 15;191(8):1325-30. Epub 2005 Mar 16.


Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.

Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D; UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group.

AIDS. 2005 Mar 25;19(5):487-94.


Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.

Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, Brumme CJ, Brumme ZL, Mo T, Alexander CS, Montaner JS.

J Infect Dis. 2005 Feb 1;191(3):339-47. Epub 2004 Dec 22.


Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy.

Verhofstede C, Noë A, Demecheleer E, De Cabooter N, Van Wanzeele F, Van Der Gucht B, Vogelaers D, Plum J.

J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):473-83.


Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing.

De Luca A, Perno CF.

Curr Opin Infect Dis. 2003 Dec;16(6):573-80. Review.


Comparison of methods for estimating the number of true null hypotheses in multiplicity testing.

Hsueh HM, Chen JJ, Kodell RL.

J Biopharm Stat. 2003 Nov;13(4):675-89.


Non-parametric methods to predict HIV drug susceptibility phenotype from genotype.

DiRienzo AG, DeGruttola V, Larder B, Hertogs K.

Stat Med. 2003 Sep 15;22(17):2785-98.


Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.

Zaccarelli M, Perno CF, Forbici F, Cingolani A, Liuzzi G, Bertoli A, Trotta MP, Bellocchi MC, Di Giambenedetto S, Tozzi V, Gori C, D'Arrigo R, De Longis P, Noto P, Girardi E, De Luca A, Antinori A.

Antivir Ther. 2003 Feb;8(1):51-6.


Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms.

Kijak GH, Rubio AE, Pampuro SE, Zala C, Cahn P, Galli R, Montaner JS, Salomón H.

HIV Med. 2003 Jan;4(1):72-8.


Controlling the rate of Type I error over a large set of statistical tests.

Keselman HJ, Cribbie R, Holland B.

Br J Math Stat Psychol. 2002 May;55(Pt 1):27-39.


Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype.

Izopet J, Souyris C, Hance A, Sandres-Sauné K, Alvarez M, Pasquier C, Clavel F, Puel J, Massip P.

J Infect Dis. 2002 May 15;185(10):1506-10. Epub 2002 Apr 30.


Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy.

Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, Facchi G, Pezzotti P, Cadeo G, Tositti G, Pasquinucci S, Pauluzzi S, Scalzini A, Salassa B, Vincenti A, Phillips AN, Dianzani F, Appice A, Angarano G, Monno L, Ippolito G, Moroni M, d' Arminio Monforte A; Italian Cohort Naive Antiretroviral (I.CO.N.A.) Study Group.

J Infect Dis. 2001 Oct 15;184(8):983-91. Epub 2001 Aug 30.


Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, Mammano F, Descamps D, Brun-Vézinet F, Clavel F.

J Virol. 2001 Jul;75(14):6410-7.


HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort.

Alexander CS, Dong W, Chan K, Jahnke N, O'Shaughnessy MV, Mo T, Piaseczny MA, Montaner JS, Harrigan PR.

AIDS. 2001 Mar 30;15(5):601-7.

Items per page

Supplemental Content

Support Center